A. Rowley

发表

A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease

G. Ousler, J. Sheppard, M. Fyfe, 2019, Clinical ophthalmology.

a phase 2 randomized , double-masked , placebo-controlled study of novel nonsystemic kinase inhibitor TOP 1630 for the treatment of dry eye disease

G. Ousler, J. Sheppard, M. Fyfe, 2019 .

Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders.

S. Hagan, M. Doughty, M. Fyfe, 2018, Investigative ophthalmology & visual science.

Effect of Narrow Spectrum Versus Selective Kinase Inhibitors on the Intestinal Proinflammatory Immune Response in Ulcerative Colitis

T. Macdonald, P. Biancheri, M. Fyfe, 2016, Inflammatory bowel diseases.

Chronic treatment with a novel γ‐secretase modulator, JNJ‐40418677, inhibits amyloid plaque formation in a mouse model of Alzheimer's disease

N. Ramsden, C. Hopf, M. Mercken, 2011, British journal of pharmacology.

γ-Secretase Pharmacology: What Pharmacology Will Work for Alzheimer's Disease?

Y. Matsuoka, B. Imbimbo, J. Toyn, 2013, International journal of Alzheimer's disease.

The Pharmacological Profile of TOP1288, a Narrow Spectrum Kinase Inhibitor (NSKI) in Clinical Development as an Anti-Inflammatory Treatment for Ulcerative Colitis

T. Macdonald, P. Biancheri, M. Fyfe, 2017 .

The Narrow Spectrum Kinase Inhibitor (NSKI) TOP1288 Demonstrates Potent Anti-Inflammatory Effects in a T Cell Adoptive Transfer Colitis Model Through a Topical Mode of Action

M. Fyfe, C. Walshe, M. Foster, 2017 .

P684 A first clinical trial of a novel narrow spectrum kinase inhibitor TOP1288 in patients with ulcerative colitis.

S. Travis, P. Irving, C. Walshe, 2017, Journal of Crohn's & colitis.

P032 The pharmacological profile of TOP1288, a narrow spectrum kinase inhibitor in clinical development as an anti-inflammatory treatment for ulcerative colitis.

T. Macdonald, P. Biancheri, M. Fyfe, 2017, Journal of Crohn's & colitis.

Narrow Spectrum Kinase Inhibitors Demonstrate Promise for the Treatment of Dry Eye Disease and Other Ocular Inflammatory Disorders.

S. Hagan, M. Doughty, M. Fyfe, 2018, Investigative ophthalmology & visual science.